Examination of the breast in women treated for nodular thyroid disorders  by Grodecka-Gazdecka, Sylwia et al.
105Rep Pract Oncol Radiother 9(4)2004
Reports of Practical
Oncology and Radiotherapy
Examination of the breast in women treated for nodular thyroid dis-
orders
1 2 1 3Sylwia Grodecka-Gazdecka, Katarzyna £¹cka, Tomasz Graja, Maciej Wawrzyniak
1Oncological Chair and Clinic, Department of Oncological Surgery, Poznañ University of Medical Sciences, ul. £¹kowa 1/2, 61-878 Poznañ, 
2 3Chair of Endocrinology and Metabolism, Poznañ University of Medical Sciences, ul. Przybyszewskiego 49, 60-355 Poznañ, ZOZ Osiek
nad Noteci¹, ul. Piêkna 1, 89-333 Osiek nad Noteci¹
Rep Pract Oncol Radiother 2004;9:105-8, original paper
nd th thReceived April 2 , 2004; received in a revised form June 8 , 2004; accepted July 16 , 2004
Summary
Ocena gruczo³u piersiowego u kobiet leczonych z powodu choroby 
guzkowej tarczycy
Streszczenie
S³owa kluczowe: rak gruczo³u piersiowego, choroby tarczycy.
The relationship between various mammary gland diseases and thyroid disorders has been the focus of interest at many research centres. 
What has been investigated are various genetic and hormonal underlying factors and conditions as well as the co-existence diseases of both 
organs.
The aim of the work was to examine the mammary gland in women treated for nodular thyroid disorders.
Material and methods: An analysis is presented comprising 269 patients with a diagnosed nodular thyroid disorders. The diagnosis
of the breast included palpation, mammography, ultrasonography. In cases of suspected lesions additionally fine-needle aspiration
and surgical biopsy were performed.
Results: Breast cancer, benign lesions and no pathology were found in 2%, 23% and 75% of all patients.
Conclusions: A significantly greater incidence of breast cancer was observed, which justifies especially careful diagnosis of the breast
in patients with a well-diagnosed thyroid disorder.
Key words: breast cancer, thyroid disorders.
Zwi¹zek pomiêdzy ró¿nymi schorzeniami gruczo³u piersiowego i chorobami tarczycy wzbudza zainteresowanie licznych oœrodków 
badawczych. Analizowane s¹ uwarunkowania genetyczne, hormonalne, jak równie¿ wspó³istnienie chorób obu narz¹dów.
Celem pracy jest ocena gruczo³u piersiowego u kobiet leczonych z powodu choroby guzkowej tarczycy.
Materia³ i metoda: W pracy przedstawiona jest analiza 269 chorych z rozpoznan¹ chorob¹ guzkow¹ tarczycy. Diagnostyka gruczo³u 
piersiowego obejmowa³a: badanie palpacyjne, mammografiê, ultrasonografiê, a w przypadku stwierdzenia zmiany dodatkowo: punkcjê 
cienkoig³ow¹ i biopsjê chirurgiczn¹.
Wyniki: U 2% badanych rozpoznano raka gruczo³u piersiowego, u 23% stwierdzono zmiany ³agodne, a u 75% nie wykryto ¿adnej patologii. 
Wnioski: Stwierdzono wyraŸnie zwiêkszon¹ zachorowalnoœæ na raka piersi, co uzasadnia szczególnie wnikliw¹ diagnostykê gruczo³u 
piersiowego u chorych z rozpoznan¹ chorob¹ tarczycy.
Proceedings from the Conference "Current Achievements in Oncology" Poznañ, 6-8 November 2003
Praca prezentowana na konferencji "Wspó³czesne Osi¹gniêcia w Onkologii" Poznañ, 6-8 listopada 2003
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Introduction and signs of macrocephaly, intestinal polips, lipomas
or "milky" spots there also appear breast and thyroid car-
Epidemiological studies cinomas. 
Among the most important epidemiological studies Mastopathy vs. simple goiter
on the relationship between thyroid disorders and breast 
diseases are those by Chen et al. [1] using the database Mizia-Stec et al. of the Œl¹sk Medical Academy [7] have 
from the Surveillance, Epidemiology and End Results investigated this problem with the use of ultrasonography. 
(SEER) study by US National Cancer Institute collected from They found goiter in 80% of patients with mastopathy. In pre-
11 regional cancer registers covering about 14% of the total menopausal women the levels of prolactine were increased 
US population. In 1973-94, 365 women patients suffering and the triiodothyronine concentrations were normal.
from thyroid and breast carcinomas were registered. On the other hand, in post-menopausal women, in addition 
In 113 cases the thyro id carc inoma was primary to higher prolactine levels, triiodothyronine concentrations 
(RR,0,99:P=0.57), whereas in 252 cases, breast cancer were lower. 
was detected as a primary tumour (RR.1.18:P=0.007).
The conclusion was that in the group of white women before Autoimmune thyroid diseases vs. breast carcinoma
menopause thyroid cancer significantly predisposes
the patients to breast cancer (RR,1.42:P=0.001). Vassilo- Thyroid autoimmune diseases associated with breast 
poulou et al. [2] investigated 41.686 patients with breast carcinoma were observed in Greek studies [8]. As many as 
cancer and 3662 women with thyroid tumours. Using statis- 43.9% of patients with breast cancer were found to have 
tical analysis they found that young women with diagnosed thyroiditis of immunologic origin.
thyroid cancer run an increased risk of carcinoma
of the breast. Li et al. [3], also on the basis of SEER, reported Hormonal disorders vs. breast and thyroid carcinomas
an increased risk of breast cancer following the diagnosis of 
thyroid cancer, particularly in women before 45 year of age. Women suffering from breast cancer often manifest hor-
Extensive epidemiological studies based on the Osaka monal disorders or disturbances. Higher estrogen and lo-
Cancer Registry, were carried out by Japanese researchers. wer gestagen in the luteal stage are often observed. Lack
Tanaka et al. [4] determined the so-called 0/E (observed/ of melatonine and thyroid hormones as well as an excess
expected) index in women patients who were found to have of prolactine have been noted. This is the reason why
primary breast cancer. Considerably higher risks of thyroid the relationship between the hormonal state and its effect
cancer (0/E=3.7; Cl [95% confidence interval]=1.8-12.9) on organs has been subjected to investigations. It was 
and ovarian cancer (0/E; 95% Cl=2.4) were observed, found that triodothyronine leads to a decrease in mammary 
particularly in a group of patients treated with hormones epithelial cell proliferation. It also has a estrogen-like effect 
for breast cancer (0/E =5.5;  95%  Cl=1.8-12.9). on the cell cycle by elevating p53 protein levels. Conse-
In Russian investigations [5], using a database of 15.627 quently, it leads to hyperphosphorylation of pRb proteins. 
women with breast cancer, it was statistically proved that the Interactions between cell lines in breast and ovarian can-
risk of breast cancer in patients with any other carcinomas cers and non-physiological hormone levels are explained 
of the mammary gland, endometrium, thyroid, lung and skin by disturbances in the binding ability of thyroid hormones 
detected earlier was increased. receptors [10].
The most frequently studied problems The aim of the work
Cowden's disease The aim of the present work is the examination
of the breast in women treated for nodular thyroid disorders.
It is a hereditary autosomal dominant syndrome forming 
various lesions in the mucosa and skin associated with fre- Material
quent co-existence of thyroid, breast and endometrium car-
cinomas. The disease is conditioned by the PTEN gene The study comprised a total of 269 patients treated
mutation in chromosome 10 (10q22-23) [6]. for thyroid nodular cancer. The largest group was that
of women aged 46 and 55 years (32%), and the smallest 
Ruvalcaba-Myhre-Smith (Bannayan-Riley-Ruvalcaba) group was that of less than 35 years of age (18%). 23 per-
syndrome cent of patients were those between 36 and 45 years of age , 
whereas 56- year-olds and older constituted 27% of the total 
This is another hereditary autosomal dominant syndrome (Figure 1). Two groups were distinguished:
also involving PTEN gene mutation. Among the symptoms Group I (230 patients) had thyroid cancer, of which 77% 
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was found to be papillary carcinoma, and Group II (39 pa- Results
tients) treated for non-malignant thyroid diseases such
as nodular goiter (67%), Hashimoto's disease or other forms As a result of the study no pathologic lesions in the breast 
of thyroiditis(23%), and Graves' disease (10%) (Figure 2, 3). were found in 75% of patients, whereas 23% women were 
found to have benign tumours. Breast carcinoma was 
detected in 2% of the total and radical oncological treatment 
was initiated.
The incidence of breast cancer in the total of 269 patients 
was 2.298 per hundred thousand, which is much higher 
than the age-related morbidity rate of 36 per hundred 
thousand of the population in Poland (Figure 4).
Discussion
Breast diseases as well as thyroid disorders are among 
the most common diseases in women. Their prevalence 
gives rise to the question whether or not they are inter-
related. Breast carcinoma is thought to be the most com-
mon malignant tumour and cause of death of cancer origin 
in women in Poland. Thyroid cancer, albeit much more 
infrequent, also presents an important medical problem. 
The high thyroid cancer morbidity rate in women implies that 
estrogens and/or progesterone may have a role in the pro-
gression of the disease of both organs. Immunohistopatho-
logic tests have confirmed the existence of steroid recep-
tors in the thyroid tisssue. Benign tumours, however, have 
been far more frequently observed. In mammary glands 
these are mostly fibrocystic disease and fibroid adenoma, 
whereas hormonally non-active adenomas are found
in the thyroid gland. In our group under investigation as ma-
ny as 25% of patients had breast diseases, of which 23% 
with thyroid nodular tumour had benign forms of breast 
Method pathology. Like other authors in most cases we found fibro-
cystic disease, in less frequent cases intratubular papillo-
Each patient included in the study had a full spectrum mas and in younger patients adenomafibromas were obser-
of medical examinations and tests of the mammary gland ved. In our study of the invasive mammary glands carcino-
carried out. These included: ma was found in 2% of patients with thyroid nodular tumours 
- palpation, detected histologically. This result, reflecting higher mor-
- mammography, bidity rate than that of the total population, has not so far 
- ultrasonography, been unequivocally accounted for, although epidemiolo-
- fine needle biopsy when lesions were found in diagno- gical studies cited in medical literature have reported its 
stic imaging, existence [1,2,3,4].
- surgical biopsy with the aim of excising the lesion and The mammary gland is among the organs which are fully 
obtaining complete histopathologic diagnosis. controlled by hormones, whereas breast cancer is a ma-
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Figure 3. Distribution of nodular thyroid disorder patients vs. microscope 
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Figure 2. The group of 230 women treated due to thyroid CA.
Figure 4. Results of distribution of breast examinations in the group 
of 269 patients investigated.
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Figure 1. Age distribution of patients with nodular thyroid disorders.
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